How to Appeal a Cigna Dupixent for Eczema Denial

You've just received a Cigna denial for Dupixent (dupilumab) for atopic dermatitis, and your dermatology practice has to decide how to respond. The patient needs this treatment and you believe the documentation supports it, but Cigna has denied coverage. Start by comparing the record with the criteria in Cigna's own published Dupixent policies, linked below.

A note on codes: Dupixent has no CPT code and no drug-specific HCPCS code. J0593 is the HCPCS code for lanadelumab (Takhzyro), a different drug, so do not use it for Dupixent. Cigna publishes a Dupixent prior authorization policy for prescription benefit coverage and a drug coverage policy for dupilumab, IP0453, which lists the unclassified HCPCS codes J3490, J3590 and C9399 for claims billed with HCPCS codes. Check which benefit the denial came from, because that decides where the appeal goes.

Why Cigna Denies Dupixent for Eczema

Understanding why Cigna denied Dupixent is the first step in building the appeal. This guide covers three denial reasons:

Inadequate Step Therapy Documentation: For initial therapy in atopic dermatitis, Cigna's published Dupixent policies (drug coverage policy IP0453, effective 06/15/2026, and the prescription benefit prior authorization policy) require that the patient tried at least one medium-, medium-high-, high- or super-high-potency prescription topical corticosteroid, applied daily for at least 28 consecutive days, with inadequate efficacy according to the prescriber. They do not list topical calcineurin inhibitors or systemic immunosuppressants as required steps. A request that does not name the steroid, its potency, how long it was applied daily and the result leaves this criterion unproven.

Insufficient Severity Criteria: Cigna's published policies measure extent rather than a score: the prescriber must estimate atopic dermatitis involvement at 10% or more of body surface area, or the patient must be 12 or older with moderate to severe hand and/or foot atopic dermatitis. The patient must also be at least 6 months old, and Dupixent must be prescribed by or in consultation with an allergist, immunologist or dermatologist. The policies set no EASI or IGA threshold, so a documented body surface area estimate matters most; EASI or IGA scores still help show severity.

Missing Quality of Life Impact Documentation: Cigna's published Dupixent criteria for atopic dermatitis do not include a quality-of-life score. Documenting the effect on sleep, work and daily activities still supports medical necessity, especially if the denial questions severity, but the appeal should lead with the criteria the policy actually lists.

What You Need to Win This Appeal

Successfully overturning a Cigna Dupixent denial requires assembling comprehensive clinical evidence that directly addresses their coverage criteria. Your appeal documentation should include:

Complete Treatment History Timeline: Compile detailed records showing all previous therapies, including specific medication names, strengths, application frequencies, treatment durations, and documented patient responses. For Cigna, the record must show at least one medium-or-higher potency prescription topical corticosteroid applied daily for at least 28 consecutive days and the prescriber's statement that it did not work well enough. Other therapies the patient tried (topical calcineurin inhibitors, phototherapy or systemic drugs) are worth listing, but they are not required steps in Cigna's published policies.

Validated Severity Assessment Scores: Include recent EASI scores or IGA ratings that demonstrate moderate-to-severe disease activity. Cigna's criterion is body surface area (10% or more), so state the prescriber's estimate explicitly; EASI or IGA scores add supporting detail. Document these assessments at multiple time points to show persistent severity despite conventional treatments.

Quality of Life Questionnaires: Utilize standardized instruments like the Dermatology Life Quality Index (DLQI) or Patient-Oriented Eczema Measure (POEM) to quantify functional impairment. These scores are supporting evidence; they are not criteria in Cigna's published Dupixent policies.

Photographic Documentation: Include clinical photographs showing affected body surface area and lesion characteristics. Visual evidence helps medical reviewers understand disease severity and distribution patterns that may not be fully captured in written documentation.

Clinical Notes Supporting Contraindications: If applicable, document any contraindications to alternative therapies or reasons why other systemic treatments are inappropriate. This strengthens the argument that Dupixent represents the most appropriate therapeutic option.

The American Academy of Dermatology's clinical guidelines for atopic dermatitis management support Dupixent use in moderate-to-severe cases where topical therapies prove inadequate, providing additional clinical authority for your appeal arguments.

Step-by-Step: Appealing Your Cigna Dupixent for Eczema Denial

Follow the procedure on the denial notice closely so your Dupixent appeal is reviewed on its merits:

File Within Required Timeframes: The deadline depends on the plan and on who is appealing. Members of ACA-compliant commercial and ERISA group health plans, or the prescriber acting as their authorized representative, have at least 180 days from the adverse benefit determination to file an internal appeal. Provider appeals under a participation contract follow the contract, and Medicare and Medicaid appeals have their own windows, stated on the denial notice. Check the contract and the denial notice, and mark the date as soon as the denial arrives.

Submit to Correct Department: Send the appeal to the address or fax number on the denial notice. A prior authorization denial under the prescription benefit and a denial of a medical claim billed with an unclassified HCPCS code can go to different places, so do not reuse an address from another Cigna appeal.

Structure Your Appeal Letter Strategically: Begin with a clear statement requesting reconsideration of the Dupixent (dupilumab) denial. Reference the original prior authorization number and member information prominently. Organize clinical arguments in the same order as Cigna's denial reasons to make medical reviewer evaluation straightforward.

Request Peer-to-Peer Review: When submitting your written appeal, simultaneously request a peer-to-peer review opportunity. During peer-to-peer discussions, focus on clinical nuances that may not be apparent from documentation alone, emphasizing how the patient's specific presentation supports Dupixent's medical necessity.

Include Complete Supporting Documentation: Attach all relevant clinical records, laboratory results, previous treatment records, and severity assessments. Assume the reviewer will decide on what you send, and make the submission complete the first time.

Sample Appeal Arguments for Dupixent for Eczema Denials

Crafting compelling clinical arguments requires aligning your documentation with Cigna's specific coverage criteria while emphasizing medical necessity:

Step Therapy Completion Argument: "The patient meets the topical corticosteroid requirement in Cigna's Dupixent policy [cite the policy the denial applied, such as IP0453]. Treatment history includes [medication and strength], a [potency class] prescription topical corticosteroid applied daily for [number] consecutive days (the policy requires at least 28) with inadequate efficacy, 6 weeks of tacrolimus 0.1% ointment with insufficient response (EASI score remained above 20), and 12 weeks of methotrexate 15mg weekly discontinued due to hepatotoxicity concerns with ALT elevation to 2.5 times upper normal limit. This comprehensive treatment history demonstrates appropriate step therapy completion warranting Dupixent consideration."

Severity Criteria Documentation: "Current disease severity meets the body surface area criterion in Cigna's Dupixent policy: the prescriber estimates involvement at 35% of body surface area, above the 10% the policy requires. An EASI score of 28.4 documents moderate-to-severe disease with extensive involvement of face, neck, and flexural areas. IGA rating of 4 (severe) confirms significant inflammatory activity with widespread erythema, papulation, and lichenification resistant to topical interventions."

Quality of Life Impact Evidence: "Functional impairment assessment using validated DLQI questionnaire reveals a score of 18, indicating severe impact on daily activities including sleep disruption (awakening 4-5 times nightly due to pruritus), work productivity loss (missing 2-3 days monthly), and social isolation due to visible lesions and associated embarrassment. This profound quality of life impact supports medical necessity for Dupixent therapy."

Clinical Guideline Support: "The American Academy of Dermatology's clinical practice guidelines specifically recommend Dupixent for moderate-to-severe atopic dermatitis inadequately controlled by topical therapies. The patient's presentation aligns precisely with published criteria supporting systemic therapy, and the treating physician chose Dupixent over conventional systemic immunosuppressants for long-term management because [clinical reason]."

Appeal letter template

Fill in the bracketed fields from the denial letter and the chart, and delete any paragraph that does not apply.

[Practice name]
[Practice address]
[Phone and fax]
NPI: [prescriber NPI]

[Date]

Cigna
Attn: [pharmacy or medical appeals unit named on the denial]
[Appeals address or fax number from the denial notice]

Re: Appeal of Dupixent (dupilumab) denial for atopic dermatitis
Patient: [patient name]
Member ID: [member ID]
Prior authorization or claim number: [number from the denial]
Date of service or request: [date]
Drug identifier: [NDC, or J3490, J3590 or C9399 as billed]

Dear Appeals Reviewer:

On behalf of [practice name] and our patient, [patient name], we request reconsideration of the [denial date] denial of Dupixent (dupilumab) for atopic dermatitis. The denial states: [denial reason as written on the notice]. The enclosed records answer that reason.

[Patient name], age [patient age], has atopic dermatitis. The prescriber estimates involvement at [percentage] of body surface area [or documents moderate to severe hand and/or foot disease]. From [start date] to [end date], the patient applied [topical corticosteroid and strength], a [potency class] prescription topical corticosteroid, daily for [number] consecutive days, with inadequate efficacy: [prescriber's assessment]. Supporting severity measures: [EASI or IGA scores, if documented]. Dupixent is prescribed by or in consultation with [name and specialty: dermatologist, allergist or immunologist].

Under [policy name and number, if the denial cites one], the plan's criteria for the topical corticosteroid trial, body surface area, age and prescriber specialty are met as follows: [each criterion and the enclosed record that shows it]. We ask that the denial be reversed and Dupixent be [approved or the claim reprocessed for payment].

Enclosures:

• Copy of the denial notice
• Treatment history with medication names, strengths, application frequency, dates and response
• Prescriber's body surface area estimate and any EASI or IGA scores
• Clinical photographs of affected areas
• DLQI or POEM results, if documented
• Notes on contraindications to alternative therapies, if applicable

Sincerely,

[Prescriber name and credentials]
[Practice name]
[Contact name, phone and email for questions about this appeal]

Key Takeaways

• Document step therapy completion meticulously: Include specific medication names, dosages, durations, and failure reasons for all previous treatments to satisfy Cigna's topical corticosteroid requirement (a medium-or-higher potency prescription steroid applied daily for at least 28 consecutive days)

• State the body surface area: Cigna's criterion is involvement of 10% or more of body surface area (or moderate to severe hand and/or foot disease at age 12 or older); EASI, IGA and DLQI scores add supporting detail

• File within the deadline that applies: members of ACA-compliant commercial plans have at least 180 days, but provider contracts set their own windows and Medicare and Medicaid appeals have their own, so check the contract and the denial notice

• Request peer-to-peer review opportunities: A physician-to-physician discussion lets the prescriber explain what the written record does not show

Tools like AI-powered appeal generators can draft your Dupixent for Eczema appeal letter in a few minutes, matching your clinical documentation to Cigna's policy criteria when one is on file.